CAR-T therapy as treatment for pancreatic ductal adenocarcinoma

Identifier:  TFG:5144

Handle: https://hdl.handle.net/20.500.11797/TFG5144

Authors:  Raquel Delgado Gil

Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a strongly fatal disease since early diagnosis is usually not possible. Since it is commonly an incurable disease, new treatments are required. This project reviews the current state of knowledge on chimeric antigen receptor (CAR) T-cell immunotherapy to treat PDAC. Several trials are discussed, establishing the importance of rightfully choosing the target antigen, the engineering of the cells, and the application of preconditioning or combinatorial therapies, among other aspects. Efficacy and toxicity depend on these factors, but the promising results published so far indicate that this therapy could be used to treat PDAC shortly.